|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
09-01-2010, 11:10 PM
|
|||
|
|||
FDA approves additional strengths of SOLODYN for inflammatory lesions treatment
Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA approves new indication for Tasigna in treatment of rare blood cancer | cancerfr | Oral Cancer | 0 | 06-18-2010 03:06 PM |
| CE 3-D US For Differentiating Focal Liver Lesions | cancerfr | Liver Cancer | 0 | 05-10-2010 02:23 PM |
| FDA approves treatment | cancerfr | Neuroblastoma | 0 | 05-04-2010 02:41 PM |
| US approves new treatment for advanced prostate cancer | cancerfr | Latest Cancer News | 0 | 04-30-2010 06:17 AM |
| FDA approves pancreatic cancer treatment | cancerfr | Pancreatic Cancer | 0 | 04-13-2010 05:26 PM |
Linear Mode
